Memantine add on to treatment of refractory obssessive compulsive disorder: A double-blind clinical trial

Memantine add on to treatment of refractory obssessive compulsive disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138712141743N1

Enrollment

Registered

2009-10-12

Start date

2009-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive- Cumpulsive Disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Memantine, 10 mg, BD, for 12 weeks. Intervention 2: placebo, 10 mg, BD,for 12 weeks.

Treatment - Drugs

Memantine, 10 mg, BD, for 12 weeks

placebo, 10 mg, BD,for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Suffering from OCD, taking a therapeutic dose of a SSRI or Clomipramine, at least for 12 weeks, Y_BOSC score of 16 or greater Exclusion criteria: primary diagnosis of psychosis or bipolar mood disorder, substance abuse or dependency, uncontrolled medical condition, having had a pervious trial of Memantine, pregnancy or breast feeding, rising liver enzymes to more than twice of normal range during intervention, presence of MDD

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: 4 weeks. Method of measurement: Y_BOCS and CGI Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hassan Hafezian

Hamadan University of medical Sciences

hhafezian@yhoo.com+98 81 1827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026